TransMedics Group (NASDAQ:TMDX) Shares Up 6.6% – Should You Buy?

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) were up 6.6% on Tuesday . The company traded as high as $64.80 and last traded at $65.10. Approximately 473,159 shares were traded during trading, a decline of 84% from the average daily volume of 2,965,165 shares. The stock had previously closed at $61.07.

Analyst Ratings Changes

A number of equities analysts have issued reports on TMDX shares. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a report on Tuesday, December 3rd. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $75.00 target price (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research report on Wednesday, December 11th. Robert W. Baird dropped their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Finally, Piper Sandler decreased their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Stock Performance

The company has a 50-day moving average of $67.70 and a 200-day moving average of $113.12. The company has a market cap of $2.25 billion, a PE ratio of 71.22 and a beta of 2.12. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same quarter in the previous year, the company earned ($0.12) EPS. The business’s revenue was up 63.7% compared to the same quarter last year. As a group, analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Transactions at TransMedics Group

In related news, insider Tamer I. Khayal sold 1,084 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the transaction, the insider now owns 20,843 shares in the company, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the sale, the director now directly owns 732 shares of the company’s stock, valued at $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

Several hedge funds and other institutional investors have recently modified their holdings of the business. Harbour Capital Advisors LLC increased its holdings in shares of TransMedics Group by 1.7% in the third quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock worth $760,000 after purchasing an additional 81 shares during the period. Venturi Wealth Management LLC grew its position in TransMedics Group by 33.7% during the third quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock worth $136,000 after buying an additional 219 shares in the last quarter. National Bank of Canada FI increased its stake in TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after acquiring an additional 262 shares during the last quarter. Quarry LP raised its holdings in shares of TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after acquiring an additional 312 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in shares of TransMedics Group by 187.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after acquiring an additional 316 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.